Celgene (BUE:CELG) Total Equity: ARS675,977.55 Mil (As of Sep. 2019)


What is Celgene Total Equity?

Celgene BUE:CELG 10 Total Equity is ARS675,977.55 Mil as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Celgene's total equity for the quarter that ended in Sep. 2019 was ARS675,977.55 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Celgene Total Equity Historical Data

* Premium members only.

The historical data trend for Celgene's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene Total Equity Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55,793.57 76,609.62 104,626.50 132,156.49 232,300.52

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178,843.14 232,300.52 319,169.85 449,068.64 675,977.55

Celgene Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Celgene's Total Equity for the fiscal year that ended in Dec. 2018 is calculated as

Total Equity=Total Assets(Q: Dec. 2018 )-Total Liabilities(Q: Dec. 2018 )
=1337773.469-1105472.952
=232,300.52

Celgene's Total Equity for the quarter that ended in Sep. 2019 is calculated as

Total Equity=Total Assets(Q: Sep. 2019 )-Total Liabilities(Q: Sep. 2019 )
=2313267.102-1637289.55
=675,977.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ARS675,977.55 Mil mean?
Celgene (BUE:CELG) has a Total Equity of ARS675,977.55 Mil as of Sep. 2019. The total amount of equity as record on a company's balance sheet. View historical data for Celgene and its competitors.
Is Celgene's Total Equity too high?
Celgene's current Total Equity is ARS675,977.55 Mil. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Total Equity compare to GILD and BIIB?
Celgene's Total Equity of ARS675,977.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Celgene and its competitors. Celgene's current Total Equity is ARS675,977.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Total Equity of ARS675,977.55 Mil. The current Total Equity is ARS675,977.55 Mil. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Total Equity is ARS675,977.55 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.